Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 194

Sort by

Sort Order Select

Journal Articles

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Waleed Alduaij, Aixiang Jiang, Diego Villa, Brett J Collinge, Susana Ben-Neriah, Merrill Boyle, Barbara Meissner, Laura K Hilton, Pedro Farinha, Graham W. Slack, Jeffrey W Craig, Alina S. Gerrie, Ciara L Freeman, Andrew J Mungall, Christian Steidl, Laurie H. Sehn, David W. Scott, Kerry J. Savage

Blood blood.2024025725.

https://doi.org/10.1182/blood.2024025725

Published: 2024

Includes: Supplemental data

Journal Articles

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH- BCL2

Brett Collinge, Susana Ben-Neriah, Laura K. Hilton, Waleed Alduaij, Tracy Tucker, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Merrill Boyle, Barbara Meissner, Diego Villa, Alina S. Gerrie, Laurie H. Sehn, Kerry J. Savage, Ryan D. Morin, Andrew J. Mungall, Christian Steidl, David W. Scott

Blood (2024) 144 (15): 1611–1616.

https://doi.org/10.1182/blood.2024025603

Published: 2024

Includes: Supplemental data

Journal Articles

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

Blood (2024) 144 (5): 525–540.

https://doi.org/10.1182/blood.2024024251

Published: 2024

Includes: Supplemental data

Journal Articles

Refining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach

Blood (2023) 142 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2023-186950

Published: 2023

Journal Articles

Multi-Dimensional Molecular and Tumor-Microenvironment Analysis of Classic Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 172.

https://doi.org/10.1182/blood-2023-174139

Published: 2023

Journal Articles

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Blood (2023) 142 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2023-184933

Published: 2023

Journal Articles

Gene Expression Profiling Reveals Two Overarching Types of Anaplastic Large Cell Lymphoma with Distinct Targetable Biology: An L.L.M.P.P. Study

Blood (2023) 142 (Supplement 1): 847.

https://doi.org/10.1182/blood-2023-186969

Published: 2023

Journal Articles

Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Matthew J. Maurer, Susan K Parsons, Jenica Upshaw, Jonathan W. Friedberg, Andrea Gallamini, Massimo Federico, Eliza A Hawkes, David Hodgson, Peter Johnson, Brian K. Link, Kerry J. Savage, Pier Luigi Zinzani, Andrew M Evens

Blood (2023) 142 (Supplement 1): 3067.

https://doi.org/10.1182/blood-2023-175079

Published: 2023

Journal Articles

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Armando Santoro, Nathalie A. Johnson, Kerry J. Savage, Abraham Avigdor, Ali Bazargan, Peter Borchmann, Robin Gasiorowski, Gareth P. Gregory, Yair Herishanu, Sumit Madan, Leonard Minuk, Gerardo Musuraca, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Pier Luigi Zinzani

Blood (2023) 142 (Supplement 1): 1725.

https://doi.org/10.1182/blood-2023-182536

Published: 2023

Journal Articles

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Armando Santoro, Alison J. Moskowitz, Silvia Ferrari, Carmelo Carlo-Stella, Julie Lisano, Stephen Francis, Rachael Wen, Alev Akyol, Kerry J. Savage

Blood (2023) 141 (22): 2780–2783.

https://doi.org/10.1182/blood.2022017951

Published: 2023

Includes: Supplemental data

Journal Articles

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

Blood (2023) 141 (20): 2493–2507.

https://doi.org/10.1182/blood.2022018248

Published: 2023

Includes: Supplemental data

Journal Articles

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano A. Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B. Cook, Francesco d’Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L. King, Young H. Ko, Ann S. LaCasce, Georg Lenz, José I. Martin-Subero, Miguel A. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier L. Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott

Blood (2022) 140 (21): 2193–2227.

https://doi.org/10.1182/blood.2022015854

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Outcomes of Patients Aged 65 Years or Older with Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) and T-Follicular Helper T-Cell Lymphoma (TFHTCL) Treated with Curative Intent CHOP(like) Chemotherapy

Henry S. Ngu, Diego Villa, Alina S. Gerrie, Christopher P. Venner, Andrew Lytle, Brian Skinnider, Jeffrey W. Craig, Graham W. Slack, David W. Scott, Laurie H. Sehn, Kerry J. Savage

Blood (2022) 140 (Supplement 1): 3713–3715.

https://doi.org/10.1182/blood-2022-168586

Published: 2022

Journal Articles

Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia

Waleed Alduaij, Aixiang Jiang, Diego Villa, Brett Collinge, Susana Ben-Neriah, Merrill Boyle, Barbara Meissner, Laura K Hilton, Pedro Farinha, Graham W Slack, Jeffrey W. Craig, Alina S. Gerrie, Ciara L. Freeman, Andrew J. Mungall, Christian Steidl, Laurie H. Sehn, David W. Scott, Kerry J. Savage

Blood (2022) 140 (Supplement 1): 1332–1333.

https://doi.org/10.1182/blood-2022-159356

Published: 2022

Journal Articles

Spatial Tumor Microenvironment Characterization and Outcome of Relapsed/Refractory Classic Hodgkin Lymphoma

Blood (2022) 140 (Supplement 1): 170–171.

https://doi.org/10.1182/blood-2022-158709

Published: 2022

Journal Articles

Development and Validation of the a dvanced-Stage H odgkin Lymphoma (HL) I nternational P rognostication I ndex (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Angie Mae Rodday, Susan K. Parsons, Jonathan W. Friedberg, Andrea Gallamini, Eliza Hawkes, David C. Hodgson, Peter Johnson, Brian K. Link, Eric Mou, Kerry J. Savage, Jenica Upshaw, Pier Luigi Zinzani, Matthew J. Maurer, Andrew M. Evens

Blood (2022) 140 (Supplement 1): 760–762.

https://doi.org/10.1182/blood-2022-164720

Published: 2022

Journal Articles

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Blood (2022) 140 (Supplement 1): 3673–3677.

https://doi.org/10.1182/blood-2022-157583

Published: 2022

Journal Articles

Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL

Blood (2022) 140 (Supplement 1): 1310–1312.

https://doi.org/10.1182/blood-2022-160187

Published: 2022

Journal Articles

Long-Term Outcomes of High-Risk Stage 1/2 Classic Hodgkin Lymphoma Managed with an Advanced Stage Treatment Approach

Jowon Laura Kim, Diego Villa, R. Petter Tonseth, Alina S. Gerrie, Don Wilson, Francois Benard, Christopher P. Venner, Brian Skinnider, Pedro Farinha, Graham W. Slack, Randy D. Gascoyne, David W. Scott, Joseph M. Connors, Laurie H. Sehn, Kerry J. Savage

Blood (2022) 140 (Supplement 1): 9437–9438.

https://doi.org/10.1182/blood-2022-162199

Published: 2022

Journal Articles

Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement?

Brett Collinge, Susana Ben-Neriah, Laura K Hilton, Waleed Alduaij, Tracy Tucker, Graham W Slack, Pedro Farinha, Jeffrey W. Craig, Merrill Boyle, Barbara Meissner, Kelly Mekwunye, Diego Villa, Alina S. Gerrie, Laurie H. Sehn, Kerry J. Savage, Ryan D. Morin, Andrew J. Mungall, Christian Steidl, David W. Scott

Blood (2022) 140 (Supplement 1): 9244–9246.

https://doi.org/10.1182/blood-2022-170065

Published: 2022

NARROW

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH- BCL2

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

Refining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach

Multi-Dimensional Molecular and Tumor-Microenvironment Analysis of Classic Hodgkin Lymphoma

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Gene Expression Profiling Reveals Two Overarching Types of Anaplastic Large Cell Lymphoma with Distinct Targetable Biology: An L.L.M.P.P. Study

Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

Genomic profiling for clinical decision making in lymphoid neoplasms

Long-Term Outcomes of Patients Aged 65 Years or Older with Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) and T-Follicular Helper T-Cell Lymphoma (TFHTCL) Treated with Curative Intent CHOP(like) Chemotherapy

Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia

Spatial Tumor Microenvironment Characterization and Outcome of Relapsed/Refractory Classic Hodgkin Lymphoma

Development and Validation of the a dvanced-Stage H odgkin Lymphoma (HL) I nternational P rognostication I ndex (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL

Long-Term Outcomes of High-Risk Stage 1/2 Classic Hodgkin Lymphoma Managed with an Advanced Stage Treatment Approach

Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only